ArticleDiabetology & metabolic syndrome2025
Association between different dimensions of the C-reactive protein-triglyceride-glucose index and future cardiovascular disease risk in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a nationwide cohort study.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association between triglyceride-glucose-related indices and cardiovascular disease risk in population with cardio-kidney-metabolic syndrome stages 0-3: a systematic review and meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- Linking the triglyceride-glucose index to major adverse cardiocerebrovascular events in individuals with cardiovascular-kidney-metabolic syndrome: insights from an aggregate-data systematic review and dose-response meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Association of C-reactive protein-triglyceride glucose index and its modified indices with stroke risk in individuals at cardiovascular-kidney-metabolic syndrome stages 0-3: a population-based cohort study.Cardiovascular diabetology · 2026Article
- Associations of the combined C-reactive protein-triglyceride glucose index and frailty index in different dimensions with incident stroke among individuals with stages 0-3 cardiovascular-kidney-metabolic syndrome.Cardiovascular diabetology · 2026Article
- The Role of the C-Reactive Protein-Triglyceride Glucose Index in Predicting New-Onset Chronic Diseases: Evidence From a Longitudinal Cohort Study.Brain and behavior · 2026Article
- Association between different dimensions of C-reactive protein-triglyceride-glucose index and the incidence of frailty in middle-aged and elderly adults in China: a nationwide prospective cohort study.Lipids in health and disease · 2026Article
- Integrative Inflammation-Metabolism Indicator for Cardiovascular-Kidney-Metabolic Syndrome: Evaluating the C-Reactive Protein-Triglyceride Glucose Index for Risk Stratification and Progression Across Three National Cohorts.Mediators of inflammation · 2026Article
- Association of the c-reactive protein-triglyceride glucose index with myocardial ischemia in patients with minimal to moderate coronary artery disease.Frontiers in medicine · 2026Article
- Association between the C-reactive protein-triglyceride-glucose index and coronary heart disease in metabolic dysfunction-associated steatotic liver disease patients: a cross-sectional study.Frontiers in endocrinology · 2026Article
- Association between the C-reactive protein-triglyceride-glucose index and the presence and prognosis of coronary microvascular dysfunction in patients with chronic coronary syndrome.Frontiers in cardiovascular medicine · 2026Article
- Clinical Significance of the C-Reactive Protein-Triglyceride-Glucose Index in Cardiovascular Disease, Stroke, Cardiovascular-Kidney-Metabolic Syndrome, Cancer, Diabetes, and Osteoporosis: A Narrative Review.International journal of general medicine · 2026Review
- Remnant cholesterol inflammatory index and cardiovascular disease among adults with cardiovascular-kidney-metabolic syndrome stages 0-3: a nationwide prospective cohort study.Scientific reports · 2025Article
- When in doubt, pig it out: a versatile translational platform to study CKD, HFpEF, and CKM syndrome.American journal of physiology. Heart and circulatory physiology · 2025Review
- The relationship between C-reactive protein-triglyceride-glucose index and cardiovascular disease: insights from the China health and retirement longitudinal study (CHARLS).Cardiovascular diabetology · 2025Article
- Associations of cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose index with incident stroke in middle-aged and older Chinese adults: a longitudinal analysis based on CHARLS.Cardiovascular diabetology · 2025Article
- The Triglyceride-glucose Index Predicts Short-Term Mortality in Critically Ill Patients With Cancer-Associated Thrombosis: A Retrospective Cohort Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular-kidney-metabolic (CKM) syndrome highlights the complex interplay between metabolic disturbances, kidney disease, and cardiovascular conditions. In this process, inflammation and insulin resistance play pivotal roles. The C-reactive protein-triglyceride-glucose index (CTI), a novel biomarker of insulin resistance and inflammation, remains unestablished for predicting cardiovascular disease (CVD) risk in CKM syndrome stages 0-3.
methodsThis study analyzed data from the China Health and Retirement Longitudinal Study. The outcome measure was self-reported CVD. The exposure measure, CTI, was calculated as: 0.412*Ln(C-reactive protein [mg/L]) + Ln[fasting triglycerides (mg/dL) * fasting glucose (mg/dL)/2]. Cumulative CTI was calculated as: (CTI 2012 + CTI 2015)/2 *Time (2015-2012). K-means clustering was used to categorize CTI fluctuations into four distinct clusters. Cox proportional hazards models were employed to examine the relationship between CTI and new-onset CVD risk in individuals across different CKM syndrome stages. The form of this relationship was further analyzed using restricted cubic splines. Additionally, the predictive ability was assessed using the receiver operating characteristic curve.
resultsThis study included 5111 individuals with CKM syndrome stages 0-3, with a mean age of 61.78 ± 8.68 years, of which 45.7%(2337) were male. During the follow-up period, 555 new cases of CVD were observed (10.9%). Our findings demonstrated a significant positive linear relationship between CTI and the risk of CVD in individuals with CKM syndrome stages 0-3. In model 3, each 1.0-SD increase in cumulative CTI was associated with a 21% increase in CVD risk (adjusted hazard ratio, aHR = 1.21 [95% CI: 1.10-1.33]). Similarly, each 1.0-SD increase in baseline CTI was associated with an 18% increase in CVD risk (aHR = 1.18 [95% CI: 1.07-1.30]). Additionally, Receiver operating characteristic analysis revealed that cumulative CTI had a better predictive performance for CVD risk compared to the cumulative TyG index (AUC: 0.596 vs 0.560, DeLong test p < 0.05).
conclusionsHigher CTI levels in individuals with CKM syndrome stages 0-3 are significantly associated with increased CVD risk. Longitudinal monitoring of CTI changes over time can help early identification of high CVD risk in this population, and its predictive value is significantly superior to that of the TyG index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.